Ojjaara (Momelotinib) is a kinase inhibitor (blocks protein kinases) indicated for the treatment of intermediate or high-risk myelofibrosis (MF), including primary MF (bone marrow blood cancer) or secondary MF [post-polycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia.
Momelotinib
Generic Name/API:Momelotinib
Packaging:30 tablets in a bottle of 100mg box
Storage:20°C to 25°C
Dosage:200 mg orally once daily with or without food. In patients with severe hepatic impairment (Child-Pugh Class C): Reduce the starting dose to 150 mg orally once daily.
Strength:Tablets: 100 mg, 150 mg, 200 mg
Indication:Ojjaara is a prescription medicine used in patients with enlarged spleen or other disease-related symptoms in adults who have myelofibrosis and moderate to severe anemia. Momelotinib is the main component in Ojjaara, which blocks the group of enzymes leading to abnormal production of blood cells and inflammation.
Ojjaara (Momelotinib) is a kinase inhibitor indicated for the treatment of intermediate or high-risk myelofibrosis (MF), including primary MF (bone marrow blood cancer) or secondary MF [postpolycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia.
Strength:
Tablets: 100 mg, 150 mg, 200 mg
Dosage:
- The recommended dosage is 200 mg orally once daily with or without food.
- In patients with severe hepatic impairment (Child-Pugh Class C): Reduce the starting dose to 150 mg orally once daily.
Adverse Effects:
- Risk of Infections and Hepatitis B Reactivation: Bacterial and viral infections, including COVID-19, Hepatitis B reactivation in patients with chronic hepatitis B virus (HBV) infection.
- Thrombocytopenia and Neutropenia: reduced levels of platelets and neutrophils.
- Hepatotoxicity: Reversible drug-induced liver injury and new or worsening elevations of Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST).
- Severe Cutaneous Adverse Reactions: Toxic epidermal necrolysis (TEN).
- Major Adverse Cardiovascular Events: Cardiovascular death, myocardial infarction, and stroke.
- Thrombosis: Risk of thrombosis, including deep venous thrombosis, pulmonary embolism, and arterial thrombosis.
- Malignancies: Risk of lymphoma and other malignancies excluding nonmelanoma skin cancer (NMSC).
Side effects:
- Thrombocytopenia: Reduced levels of platelets.
- Hemorrhage: Bleeding can occur.
- Bacterial infection: The Patient can be prone to infections
- Fatigue and dizziness: Feeling unusually tired or lacking energy
- Diarrhea and nausea: Digestive issues are frequent.
Storage:
20°C to 25°C.
- Infections (Bacterial and viral infections): Ojjaara can cause bacterial and viral infections, including COVID-19. Hepatitis B reactivation is observed in patients taking ojjaara with chronic hepatitis B virus.
- Blood problem (Thrombocytopenia and Neutropenia): Ojjaara can reduce levels of platelet count and neutrophils.
- Liver problem (Hepatotoxicity): Very rarely, Ojjaara can cause reversible drug-induced liver injury but new or worsening elevations of Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) are common findings
- Skin problems (Severe Cutaneous Adverse Reactions): Severe skin changes are seen, including toxic epidermal necrolysis (TEN) in the patients who take ojjaara.
- Heart problems (cardiovascular diseases): Ojjaara can cause Cardiovascular death, myocardial infarction, and stroke.
- Bleeding diseases (Thrombosis): Ojjaara can cause thrombosis, including deep venous thrombosis, pulmonary embolism, and arterial thrombosis.
- Cancers (Malignancies): Ojjaara can cause lymphoma and other malignancies excluding nonmelanoma skin cancer (NMSC).
FAQ
How does Ojjaara work to fight cancer?
Ojjaara (Momelotinib) is the main component in Ojjaara, which blocks the group of enzymes (proteins) called Janus kinases (JAKs), leading to abnormal production of blood cells and inflammation.
How is Ojjaara supplied, and what is its dosage?
200 mg orally once daily with or without food is the recommended dose of Ojjaara. (Reduce the starting dose to 150 mg orally once daily in severe hepatic impairment (Child-Pugh Class C): Your doctor will determine the precise dose based on your medical condition and response to treatment.
What are the most common side effects of Ojjaara?
The most common side effects of Ojjaara (Momelotinib) are thrombocytopenia (low number of platelets), hemorrhage, bacterial infection, fatigue, dizziness, diarrhea, and nausea. Your doctor will modify the dosage to manage these side effects.
What are the serious side effects for which I should consult the doctor?
Serious side effects can include infections, including reactivation of Hepatitis B, thrombocytopenia, neutropenia, hepatotoxicity, severe cutaneous adverse reactions, major adverse cardiovascular events, thrombosis (formation of a blood clot inside the vein), and malignancies. It’s crucial to inform the doctor immediately of any unusual symptoms.
Can pregnant women or breastfeeding mothers take Ojjaara?
Ojjaara, when taken in pregnancy, may lead to fetal harm. It is advised to avoid this medicine for lactating mothers.
Will I need to be monitored more closely while taking Ojjaara?
Yes, this monitoring can include regular blood tests (to check liver enzymes, red and white blood cell counts), monitoring for symptoms of skin changes, heart changes, bleeding changes and malignancies.
What is the price of Ojjaara (Momelotinib) tablets in India?
The Momelotinib (Ojjaara) tablets price in India varies because it is not locally marketed and needs to be sourced through verified international suppliers. Pricing depends on stock availability, global market fluctuations and import-related factors. For the latest and most accurate cost, contact 24/7QualityMeds at +91 9967979080.
How to buy Ojjaara (Momelotinib) tablets online in India?
To buy Ojjaara (Momelotinib) tablets online in India at a genuine price, reach out to 24/7QualityMeds. We help patients with compliant procurement from authorized sources and ensure secure, reliable delivery.
